In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Lack of impact on responsiveness to clopidogrel and aspirin of improving glycaemic control in patients with type 2 diabetes mellitus and stable coronary artery disease on dual antiplatelet therapy

Session Poster session 6

Speaker Ana Marcano

Congress : ESC Congress 2017

  • Topic : preventive cardiology
  • Sub-topic : Metabolic Syndrome, Insulin, Insulin Resistance
  • Session type : Poster Session
  • FP Number : P5357

Authors : AL Marcano (L'Hospitalet de Llobregat, Barcelona,ES), M Gracida (L'Hospitalet de Llobregat, Barcelona,ES), P San Jose (L'Hospitalet de Llobregat, Barcelona,ES), LM Lugo (L'Hospitalet de Llobregat, Barcelona,ES), M Guerrero (L'Hospitalet de Llobregat, Barcelona,ES), G Roura (L'Hospitalet de Llobregat, Barcelona,ES), J Gomez-Lara (L'Hospitalet de Llobregat, Barcelona,ES), JA Gomez-Hospital (L'Hospitalet de Llobregat, Barcelona,ES), JL Ferreiro (L'Hospitalet de Llobregat, Barcelona,ES), E Montanya (L'Hospitalet de Llobregat, Barcelona,ES), AR Cequier (L'Hospitalet de Llobregat, Barcelona,ES)

A.L. Marcano1 , M. Gracida1 , P. San Jose2 , L.M. Lugo1 , M. Guerrero2 , G. Roura1 , J. Gomez-Lara1 , J.A. Gomez-Hospital1 , J.L. Ferreiro1 , E. Montanya2 , A.R. Cequier1 , 1Bellvitge University Hospital - IDIBELL, Heart Diseases Institute - L'Hospitalet de Llobregat, Barcelona - Spain , 2Bellvitge University Hospital. University of Barcelona. CIBERDEM, Department of Endocrinology - L'Hospitalet de Llobregat, Barcelona - Spain ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 1131

Background: Reduced clopidogrel- and aspirin-induced platelet inhibition has been described in patients with type 2 diabetes mellitus (T2DM) compared to non-diabetic patients, especially in those with poor glycaemic control. However, whether optimizing glycaemic control in such patients may reduce platelet reactivity and improve responsiveness to antiplatelet agents has not been evaluated to date.

Purpose: To investigate the impact of improving glycaemic control on platelet reactivity in patients with T2DM and coronary artery disease (CAD) receiving dual antiplatelet therapy with aspirin and clopidogrel.

Methods: Prospective pharmacodynamic (PD) investigation with a before and after design conducted in patients with T2DM with poor glycemic control and CAD treated with aspirin and clopidogrel. Glycosylated hemoglobin (HbA1c) of ≥7.5% was considered poor glycemic control. Patients were included in a specific optimization program of 4 months duration. The program was based on lifestyle and dietary instructions and adjustment of hypoglycemic treatment in the Endocrine Unit outpatient clinic. Blood samples were collected at baseline and at the end of the program in order to assess both metabolic status and platelet reactivity. Platelet function tests performed included: a) Light Transmittance Aggregometry (LTA) using ADP 5 (primary endpoint) and 20mmol, arachidonic acid (AA) and collagen as agonists; b) VASP analysis; c) Multiple electrode aggregometry (MEA) using ADP and AA as agonists; and d) The VerifyNow (VN) system.

Results: A total of 37 patients with valid PD data were included. Mean HbA1c levels were improved during the study (baseline: 8.5±0.2% vs. end of the program: 7.4±0.2%; p<0.001), as well as other glycaemic parameters of metabolic control, such as preprandial and peak postprandial blood glucose, and glucose variability (maximum amplitude of glycaemic excursion, MAGE). The optimization of glycaemic control was not reflected in an improvement in responsiveness to clopidogrel or aspirin. In particular, no differences were observed in platelet reactivity before and after the program as measured with LTA ADP 5mmol (36.0±2.2% vs. 36.6±2.0%; p=0.760) or any of the other platelet function tests (Figure) or agonists employed. No significant differences were observed in exploratory subgroup analyses stratifying patients according to the following variables (dichotomizing when standard cutoff values applied and/or per quartiles): duration of T2DM (<10 vs. ≥10 years), HbA1c, preprandial capillary blood glucose, peak postprandial capillary blood glucose, and MAGE.

Conclusions: Optimization of glycaemic control in patients with T2DM and CAD did not result in a short-term improvement on clopidogrel- or aspirin-mediated platelet inhibition.

PD impact of glycaemic control

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are